Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving…
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial…
